Recent Quotes (30 days)

You have no recent quotes
chg | %

LivaNova PLC  

(Public, LON:LIVN)   Watch this stock  
Find more results forLIVN
-1.75 (-3.52%)
Feb 24 - Close
LON real-time data - Disclaimer
Currency in USD
Range     -
52 week 41.21 - 63.00
Open     -
Vol / Avg. 0.00/390.00
Mkt cap 2,384.34M
P/E     -
Div/yield     -
EPS -1.09
Shares 48.18M
Beta     -
Inst. own     -
Feb 20, 2017
Q4 2016 LivaNova PLC Earnings Release (Estimated)
Dec 7, 2016
LivaNova PLC at Berenberg European Conference
Nov 29, 2016
LivaNova PLC at Piper Jaffray Healthcare Conference - Webcast

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 3.92% -
Operating margin 7.78% -
EBITD margin - -
Return on average assets 1.85% -
Return on average equity -0.35% -
Employees 4,700 -
CDP Score - -


20 Eastbourne Terrace
United Kingdom - Map
+44-20-37865275 (Phone)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


LivaNova PLC is a medical technology company. The Company operates through three segments: Cardiac Surgery, Cardiac Rhythm Management (CRM) and Neuromodulation. The Cardiac Surgery business unit is engaged in the development, production and sale of cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems and systems for autotransfusion and autologous blood washing. The CRM business unit develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failure. CRM offers products, including leads and delivery systems, and information systems. The Neuromodulation business unit designs, develops and markets neuromodulation-based medical devices for the treatment of epilepsy and depression. Through the Neuromodulation business unit, the Company markets its implantable VNS Therapy systems that deliver vagus nerve stimulation therapy for the treatment of epilepsy and depression.

Officers and directors

Damien McDonald Chief Executive Officer, Chief Operating Officer, Director
Age: 51
Vivid Sehgal Chief Financial Officer
Michel Darnaud President - Cardiac Surgery
Stefano Di Lullo President - Cardiac Rhythm Management
Jacques Gutedel President - Intercontinental
Age: 56
Rohan H. Hoare Ph.D. President - Neuromodulation
Age: 50
Brian Sheridan Senior Vice President, General Counsel, Company Secretary
David S. Wise Senior Vice President - Human Resources & Information Technology
Edward Andrle Senior Vice President - Strategy & Business Development
Pritpal Shinmar Senior Vice President - Global Market Access